Drug
Epalrestat clinical trials
- studies test it
- 5
- open now
- 2
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the epalrestat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
Haibo Shao (1) · The Third Xiangya Hospital of Central South University (1) · Maggie's Pearl, LLC (1) · Sun Yat-sen University (1) · Xiangya Hospital of Central South University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses epalrestat is read from its arms, and is right about nine times in ten.
Testing it · 5
- Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingPhase 2Haibo ShaoNCT07557914Written as Epalrestat
- Research of SORD-CMT Natural History and Epalrestat TreatmentNot yet recruitingPhase 2The Third Xiangya Hospital of Central South UniversityNCT05777226Written as Epalrestat
- Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDGTerminatedPhase 3Maggie's Pearl, LLCNCT04925960Written as Epalrestat
- Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic PatientsStatus unknownPhase 4Xiangya Hospital of Central South UniversityNCT05184049Written as Epalrestat,Mecobalamin
- Evaluation of Epalrestat in Metastatic Triple-negative Breast CancerTerminatedPhase 2Sun Yat-sen UniversityNCT03244358Written as Epalrestat
Codes
What other systems call epalrestat · ClinicalTrials.gg INT003087
- MeSH (NLM) C038131epalrestatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 424DV0807XEPALRESTATConfirmed FDA, NLM, Wikidata
- Wikidata Q5382029epalrestatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72762EpalrestatOne source FDA
- DrugBank DB15293One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C038131 | epalrestat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 424DV0807X | EPALRESTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5382029 | epalrestat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72762 | Epalrestat | One source FDA |
| DrugBank | DB15293 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.